Sell / TrimIPNP
Pharmaceuticals & Biotechnology
Ipsen SA
Recommends selling the holding, citing Somatuline generic competition, product concentration and acquisition risk, with a €135 target price.
Giorgio Donzelli
24 Sept 2026 · 8 pages
How the fund is managed
An analyst writes an investment paper, which the relevant sector leader reviews before it is presented at an in-person board meeting. The Internal Board votes on the recommendation. If approved, the trade is placed with the broker through the Club’s execution-only account. Trades and portfolio changes are recorded in the termly newsletter and annual report.
Holyport students sit on the Internal Board alongside Eton students. They research companies, present recommendations and vote on trades; decisions belong to the student board, not the external advisors.
Research
Latest from our analysts
Buy, sell and macro papers written by members, each presented to the board before any trade.
Sell / TrimNOVO
Healthcare
Novo Nordisk
Recommends selling Novo Nordisk at a US$94.50 target price against a US$114.30 share price, examining competition from Eli Lilly, lower US prices and semaglutide patent expiry.
Koichi Sakamoto, Yohan Jegou
24 Sept 2026 · 13 pages
Buy8001.T
Consumer & Trading
Itochu Corporation
Japan's diversified trading conglomerate, spanning textiles, metals, food, energy and ICT. Recommends a £2,200 position (about 4% of the portfolio) with a ¥2,457 target price.
Alex Arbuthnott
4 Jun 2026 · 14 pages
Sell / TrimIQV
Healthcare
IQVIA Holdings
A global leader in healthcare data and contract research ($170.93 per share, $29B market cap). Sets out the case to sell or trim the holding.
James Saunders
12 Mar 2026 · 9 pages
The live portfolio
Follow the fund’s value, cash balance and sector allocation.
ECHCIC Investment Challenge
In 2025–26, around 200 students from 6 schools competed, with the competition run by our own student committee.